Clinical trial

S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent…

NCT00100789 · SWOG Cancer Research Network, Other · Completed

Key facts

NCT number NCT00100789
Title S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
Official title A Phase II Study of Biweekly Gemcitabine and Paclitaxel (GEMTAX) Combination in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Lead sponsor SWOG Cancer Research Network, Other
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Phase Phase 2
Study type Interventional
Conditions Head and Neck Cancer
Intervention type Drug
Interventions gemcitabine, paclitaxel
Enrollment 67
Start date Jan 1, 2005
Primary completion Feb 1, 2008
Completion Feb 1, 2008
First posted Jan 7, 2005
Last update posted Oct 1, 2012
Countries United States

At a glance

  • 100–999 Study sites
  • Yes Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies